Hydrogen peroxide, 90%

RTECS #

MX0900000

CAS #

7722-84-1
See: NMAM or OSHA Methods

Updated

March 2019

Molecular Weight

34.02

Molecular Formula

H₂O₂

Synonyms

Albone
Dihydrogen dioxide
Hioxyl
Hydrogen dioxide
Hydrogen peroxide
Hydrogen peroxide (ACGIH:OSHA)
Hydroperoxide
Inhibine
Oxydol
Perhydrol
Perone
Perossido di idrogeno (Italian)
Peroxan
Peroxide
Peroxyde d'hydrogene (French)
Superoxol
T-Stuff
Wasserstoffperoxid (German)
Waterstofperoxyde (Dutch)

Skin and Eye Irritation and References

Route/Organism	Dose	Effect	Reference
eye /rabbit	1 mg	severe	JTPAE7 29,308,2001

Mutation Data and Reference

System Test	Route/Organism/Tissue	Dose	Reference
Cytogenetic Analysis	Ascites tumor/mouse	10 mmol/L	MUREAV 4,385,1967
Cytogenetic Analysis	embryo/mouse	10 µmol/L	IDZAAW 56,1,1981
Cytogenetic Analysis	ovary/hamster	1 mmol/L	CALEDQ 5,199,1978
Cytogenetic Analysis	lung/hamster	100 µmol/L	IDZAAW 56,1,1981
Cytogenetic Analysis	embryo/hamster	100 µmol/L	IDZAAW 56,1,1981
Cytogenetic Analysis	fibroblast/hamster	250 mg/L	ESKHA5 (96),55,1978
Cytogenetic Analysis	other cell types/human	1.5 mg/L/4H	MUREAV 578,100,2005
Cytogenetic Analysis	lymphocyte/human	30 µmol/L/30M	MUREAV 559,97,2004
Cytogenetic Analysis	ovary/hamster	0.3 mmol/L/1H	MUREAV 649,114,2008
Cytogenetic Analysis	lymphocyte/human	10 µmol/L/2H	MUREAV 669,155,2009
DNA adduct	embryo/hamster	0.09 µmol/L/1H	MUREAV 563,35,2004
DNA adduct	lymphocyte/human	25 µmol/L/1H	MUREAV 582,155,2005
DNA adduct	other cell types/human	50 µmol/L/4H	CNREA8 69,3052,2009
DNA Damage	lymphocyte/human	0.3 mg/L/1H	FCTOD7 49,763,2011
DNA Damage	mammary gland/human	50 µmol/L/10M	FCTOD7 48,1092,2010
DNA Damage	other cell types/human	50 µmol/L/10M	FCTOD7 48,1092,2010
DNA Damage	/Saccharomyes cerevisiae	10 mmol/L/20M	FCTOD7 49,1361,2011
DNA Damage	leukocyte/human	300 µmol/L/2H	MUREAV 726,146,2011
DNA Damage	oral/Drosophila melanogaster	50 µmol/L/24H- intermittent	MUREAV 726,222,2011
DNA Damage	lymphocyte/human	10 µmol/L (+/-enzymatic activation step)	MUREAV 743,25,2012
DNA Damage	sperm/human	10 µmol/L (+/-enzymatic activation step)	MUREAV 743,25,2012
DNA Damage	other cell types/mouse	200 µmol/L/30M	TIHEEC 25,5,2009
DNA Damage	lymphocyte/human	70 µmol/L/40M	MUREAV 724,41,2011
DNA Damage	other cell types/human	70 µmol/L/60M	MUREAV 724,41,2011
DNA Damage	lymphocyte/human	10 µmol/L/5M	MUREAV 748,60,2012
DNA Damage	lymphocyte/human	10 µmol/L	FCTOD7 49,2947,2011
DNA Damage	other cell types/human	10 µmol/L/5M	MUREAV 749,70,2012
DNA Damage	other cell types/mouse	0.25 mmol/L/5M	FCTOD7 50,2275,2012
DNA Damage	HeLa cell/human	300 µmol/L/1H	FCTOD7 50,3475,2012
DNA Damage	fibroblast/mouse	10 µmol/L/10M	MUREAV 745-746,16,2013
DNA Damage	other cell types/human	1 µmol/L/12H	MUTAEX 28,515,2013
DNA Damage	other cell types/human	80 µmol/L/4H	MUTAEX 28,583,2013
DNA Damage	/Schizosaccharomyces pombe	1 mmol/L/30M	EMMUEG 54,327,2013
DNA Damage	fibroblast/hamster	100 µmol/L/1H	MUREAV 747,86,2012
DNA Damage	lymphocyte/man	25 µmol/L/5M	TIVIEQ 26,369,2012
DNA Damage	lymphocyte/rat	5 µmol/L/2H	MUREAV 761,10,2014
DNA Damage	lymphocyte/rat	5 µmol/L/4H	MUREAV 761,10,2014
DNA Damage	lymphocyte/non-mammalian species	50 µmol/L/1H	MUREAV 754,22,2013
DNA Damage	fibroblast/hamster	100 µmol/L/10M	TIVIEQ 27,864,2013
DNA Damage	other cell types/human	50 µmol/L/24H	NRTXDN 33,1086,2012
DNA Damage	fibroblast/human	80 µmol/L/3H	TIVIEQ 28,31,2014
DNA Damage	leukocyte/human	25 µmol/L/15M	TIVIEQ 28,451,2014
DNA Damage	other cell types/human	10 µmol/L	MUREAV 745,6,2013
DNA Damage	other cell types/human	50 µmol/L/20M	MUREAV 791,12,2015
DNA Damage	lung/human	25 µmol/L/24H	TIVIEQ 26,752,2012
DNA Damage	other cell types/rat	1.7 mg/L/20M	MUREAV 814,29,2017
DNA Damage	multiple/other fish	100 mmol/L/10M	MUTAEX 28,601,2013
DNA Damage	lung/human	15 µmol/L/30M	MUTAEX 28,699,2013
DNA Damage	other cell types/human	10.5 mg/L/24H	TOLED5 239,194,2015
DNA Damage	other cell types/other fish	2.5 µmol/L/10M	MUREAV 826,25,2018
DNA Damage	fibroblast/hamster	50 µmol/L/30M	FCTOD7 113,90,2018
DNA Damage	lymphocyte/human	30 pph	TIVIEQ 29,779,2015
DNA Damage	other cell types/human	300 µmol/L/2H	TIVIEQ 29,1503,2015
DNA Damage	ovary/hamster	50 µmol/L/1H	MUREAV 822,10,2017
DNA Damage	fibroblast/hamster	1.7 mg/L/20M	MUREAV 814,29,2017
DNA Damage	lung/human	50 µmol/L/5M	TOLED5 276,48,2017
DNA Damage	fibroblast/mouse	200 µmol/L/30M	TOLED5 276,129,2017
DNA Damage	liver/mouse	50 µmol/L/1H	TOXID9 44,153,2005
DNA Damage	fibroblast/human	50 mmol/L/1H	TOLED5 147,35,2004
DNA Damage	lymphocyte/human	100 µmol/L/3M	MUREAV 587,52,2005
DNA Damage	other cell types/human	100 µmol/L/3M	MUREAV 587,52,2005
DNA Damage	embryo/salmon	5 µmol/L/1H	MUREAV 563,89,2004
DNA Damage	other cell types/mouse	200 µmol/L/1H (-enzymatic activation step)	MUREAV 541,9,2003
DNA Damage	ovary/hamster	200 µmol/L/5M	MUREAV 560,41,2004
DNA Damage	mammary gland/human	9.8 mg/L/24H (-enzymatic activation step)	MUREAV 588,47,2005
DNA Damage	fibroblast/mouse	500 µmol/L/1H	FCTOD7 44,261,2006
DNA Damage	other cell types/human	200 µmol/L/60M	MUREAV 577S,1,2005
DNA Damage	other cell types/human	2000 µmol/L/3H (-enzymatic activation step)	MUTAEX 20,193,2005
DNA Damage	other cell types/rat	75 µmol/L/5M	TOLED5 159,212,2005
DNA Damage	lymphocyte/rat	50 µmol/L/5M	TOLED5 164,54,2006
DNA Damage	testis/rat	50 µmol/L/5M	TOLED5 164,54,2006
DNA Damage	lung/rat	50 µmol/L/5M	TOLED5 164,54,2006
DNA Damage	liver/rat	50 µmol/L/5M	TOLED5 164,54,2006
DNA Damage	other cell types/woman	1 mmol/L/1H	TXCYAC 222,71,2006
DNA Damage	lung/hamster	150 µmol/L/1H	MUREAV 631,44,2007
DNA Damage	liver/human	1 mmol/l/48H	MUREAV 696,21,2010
DNA Damage	liver/human	0.316 mmol/l/48H	MUREAV 696,21,2010
DNA Damage	liver/human	56 µmol/L/10M	MUREAV 657,133,2008
DNA Damage	lymphocyte/human	1 µmol/L/2H	TOSCF2 72,283,2003
DNA Damage	fibroblast/human	250 µmol/L/5M	MUREAV 677,46,2009
DNA Damage	lymphocyte/human	25 µmol/L/30M (-enzymatic activation step)	FCTOD7 48,320,2010
DNA Damage	lymphocyte/human	5 µmol/L/10M	MUREAV 652,46,2008
DNA Damage	fibroblast/human	20 µmol/L/15M	MUREAV 701,103,2010
DNA Damage	lymphocyte/human	20 µmol/L/15M	MUREAV 701,103,2010
DNA Damage	fibroblast/hamster	40 µmol/L/15M	MUREAV 701,103,2010
DNA Damage	liver/human	40 µmol/L/15M	MUREAV 701,103,2010
DNA Damage	HeLa cell/human	40 µmol/L/15M	MUREAV 701,103,2010
DNA Damage	other cell types/rat	100 µmol/L/20M	NRSCDN 151,518,2008
DNA Damage	leukocyte/human	200 µmol/L/5M	MUREAV 718,56,2011
DNA Damage	other cell types/mouse	190 µmol/L/4H	MUREAV 678,123,2009
DNA Damage	other cell types/human	25 µmol/L/30M	TOLED5 170,57,2007
DNA Damage	lymphocyte/rat	50 µmol/L/10M	MUREAV 564,75,2004
DNA Damage	mammary gland/human	100 µmol/L/5M	TXAPA9 232,169,2008
DNA Damage	fibroblast/human	100 µmol/L/20M	MUREAV 546,93,2004
DNA Damage	other cell types/rat	100 µmol/L/10M	MUREAV 634,51,2007
DNA Damage	other cell types/rat	1 mmol/L/30M	NRTXDN 28,886,2007
DNA Damage	other cell types/rat	0.1 mmol/L/6H	NRTXDN 28,886,2007
DNA Damage	other cell types/mouse	50 µmol/L	MUTAEX 20,469,2005
DNA Damage	lymphocyte/human	5.0 mg/L/48H	MUREAV 607,160,2006
DNA Damage	other cell types/hamster	40 µmol/L/1H	MUREAV 559,39,2004
DNA Damage	ovary/hamster	20 µmol/L	MUREAV 299,95,1993
DNA Damage	lung/hamster	353 µmol/L	NATUAS 282,318,1979
DNA Damage	other cell types/cattle	25 µmol/L	MUREAV 240,35,1990
DNA Damage	lymphocyte/mammal (species unspecified)	600 µmol/L	DECRDP 8,1,1982
DNA Damage	lung/human	300 µmol/L/1H	MUREAV 515,99,2002
DNA Damage	liver/rat	300 µmol/L/1H	MUREAV 515,99,2002
DNA Damage	other cell types/human	100 µmol/L/3H	MUTAEX 16,439,2001
DNA Damage	other cell types/rat	10 µmol/L/24H	ATSUDG 75,243,2001
DNA Damage	other cell types/human	10 µmol/L/15M	MUREAV 519,151,2002
DNA Damage	lung/hamster	200 µmol/L/24H	ARTODN 75,604,2001
DNA Damage	lymphocyte/human	0.01 mmol/L/1H	MUREAV 535,25,2003
DNA Damage	other cell types/human	0.01 mmol/L/1H	MUREAV 535,25,2003
DNA Damage	other cell types/mouse	0.01 mmol/L/1H	MUREAV 535,25,2003
DNA Damage	lymphocyte/human	0.01 mmol/L/30M	TCMUD8 20,11,2000
DNA Damage	/Escherichia coli	0.001 µmol/plate/2H	MUREAV 535,171,2003
DNA Damage	other cell types/other fish	0.001 mmol/L/5M	MUREAV 534,165,2003
DNA Damage	other cell types/non-mammalian species	0.04 mmol/L/1H	MUREAV 539,19,2003
DNA Damage	sperm/human	80 µmol/L/1H	MUREAV 544,173,2003
DNA Damage	fibroblast/mouse	25 µmol/L/15M	MUREAV 531,165,2003
DNA Damage	other cell types/non-mammalian species	44 µmol/L/20M	MUREAV 542,15,2003
DNA Damage	other cell types/rat	200 µmol/L	CRNGDP 20,629,1999
DNA Damage	other cell types/mouse	100 µmol/L	JCINAO 77,1312,1986
DNA Damage	other cell types/mouse	1 µmol/L	CRNGDP 4,1507,1983
DNA Damage	lymphocyte/mouse	2 mmol/L	MUREAV 203,155,1988
DNA Damage	fibroblast/human	28 µmol/L	BBACAQ 781,56,1984
DNA Damage	leukocyte/human	20 µmol/L	MUREAV 265,255,1992
DNA Damage	/Bacillus subtilis	50 mmol/L	BBACAQ 155,476,1968
DNA Damage	/Other microorganisms	1 mmol/L	MUREAV 368,235,1996
DNA Damage	/Neurospora crassa	50 µmol/L	MUREAV 405,29,1998
DNA inhibition	other cell types/human	1200 µmol/L	CNREA8 45,2522,1985
DNA inhibition	other cell types/mouse	40 µmol/L	JCINAO 77,1312,1986
DNA inhibition	fibroblast/human	1 mg/L	CRNGDP 4,1317,1983
DNA repair	/Salmonella typhimurium	2 mmol/L/60M	MUREAV 502,11,2002
DNA repair	other cell types/human	10 mmol/L/10M	MUREAV 537,1,2003
DNA repair	fibroblast/human	20 µmol/L/1H	MUREAV 513,159,2002
DNA repair	/Escherichia coli	14630 µg/well/16H	CBINA8 15,219,1976
DNA repair	other cell types/human	10 µmol/L/20M	MUREAV 577S,1,2005
DNA repair	other cell types/other fish	10 µmol/L/10M	MUREAV 753,107,2013
DNA repair	other cell types/human	1 µmol/L/12H	MUTAEX 28,515,2013
DNA repair	fibroblast/mouse	5 µmol/L/6D	MUREAV 745-746,16,2013
DNA repair	lymphocyte/human	100 µmol/L	MUREAV 724,46,2011
gene conversion and mitotic recombination	other cell types/Drosophila melanogaster	120 mmol/L	FCTOD7 50,1384,2012
gene conversion and mitotic recombination	/Saccharomyes cerevisiae	5 pph	AGACBH 4,286,1974
micronucleus test	other cell types/human	10 µmol/L	MUREAV 577S,1,2005
micronucleus test	lung/hamster	150 µmol/L/1H	MUREAV 631,44,2007
micronucleus test	ovary/hamster	500 µmol/L/24H (-enzymatic activation step)	MUREAV 630,1,2007
micronucleus test	embryo/hamster	5 mg/L/4H (-enzymatic activation step)	MUREAV 561,153,2004
micronucleus test	lymphocyte/human	3.4 mg/L/24H	EMMUEG 43,45,2004
micronucleus test	lymphocyte/human	30 µmol/L/30M	MUREAV 559,97,2004
micronucleus test	other cell types/mouse	20 µmol/L/4H	MUREAV 678,123,2009
micronucleus test	other cell types/rat	1.7 mg/L/20M	MUREAV 814,29,2017
micronucleus test	fibroblast/hamster	1.7 mg/L/20M	MUREAV 814,29,2017
micronucleus test	other cell types/human	300 µmol/L/24H	TIVIEQ 29,1503,2015
micronucleus test	lymphocyte/human	50 µmol/L/48H	FCTOD7 113,90,2018
micronucleus test	fibroblast/hamster	50 µmol/L/18H	FCTOD7 113,90,2018
micronucleus test	lung/human	25 µmol/L/24H	TIVIEQ 26,752,2012
micronucleus test	other cell types/human	40 µmol/L/4H	MUTAEX 28,583,2013
micronucleus test	other cell types/human	40 µmol/L	MUTAEX 28,583,2013
micronucleus test	lymphocyte/pig	10 µmol/L/72H	MUREAV 653,124,2008
morphological transform	liver/rat	100 µmol/L/7W	MOCAE8 30,209,2001
morphological transform	embryo/mouse	20 µmol/L	CRNGDP 10,1055,1989
morphological transform	embryo/hamster	2500 µg/L	MUREAV 356,85,1996
mutation in mammalian somatic cells	lung/hamster	10 µmol/L	CRNGDP 10,1055,1989
mutation in mammalian somatic cells	kidney/monkey	7 mmol/L	CRNGDP 11,283,1990
mutation in mammalian somatic cells	lymphocyte/mouse	18600 nmol/L	MUTAEX 3,193,1988
mutation in microorganisms	/Schizosaccharomyces pombe	2820 mmol/L (-enzymatic activation step)	ADWMAX -,193,1962
mutation in microorganisms	/Bacillus subtilis	5 ppm (-enzymatic activation step)	MUREAV 95,191,1982
mutation in microorganisms	/Salmonella typhimurium	6 µg/plate (-enzymatic activation step)	ABCHA6 44,1989,1980
mutation in microorganisms	/Escherichia coli	5 pph (-enzymatic activation step)	AGACBH 4,286,1974
mutation in microorganisms	/Saccharomyes cerevisiae	10 mg/L (-enzymatic activation step)	MUREAV 33,147,1975
mutation in microorganisms	/Neurospora crassa	210 mmol/L/30M (-enzymatic activation step)	PNASA6 35,581,1949
mutation in microorganisms	/Haemophilus influenzae	800 µmol/L (-enzymatic activation step)	MUREAV 30,9,1975
mutation in microorganisms	/Other microorganisms	6 ppm/1H-continuous (-enzymatic activation step)	JOBAAY 54,767,1947
mutation in microorganisms	/Other microorganisms	6 ppm (-enzymatic activation step)	POASAD 34,114,1953
mutation in microorganisms	/Bacillus subtilis	5 pph/15M	MUREAV 503,77,2002
mutation in microorganisms	/Salmonella typhimurium	1.87 mg/plate/30M	MUREAV 535,171,2003
mutation in microorganisms	/Salmonella typhimurium	25 µg/plate/48H (+/-enzymatic activation step)	MUREAV 539,29,2003
mutation in microorganisms	/Escherichia coli	100 µg/plate/48H (+/-enzymatic activation step)	MUREAV 539,29,2003
mutation in microorganisms	/Salmonella typhimurium	34000 ng/plate/72H	MUREAV 542,49,2003
mutation in microorganisms	/Salmonella typhimurium	500 µg/plate/66H (-enzymatic activation step)	EMMUEG 40,63,2002
mutation in microorganisms	/Salmonella typhimurium	51 µg/plate/72H (-enzymatic activation step)	MUTAEX 15,495,2000
mutation in microorganisms	/Salmonella typhimurium	20 µL/plate/30M	DCTODJ 27,157,2004
mutation in microorganisms	/Salmonella typhimurium	2.6 mmol/L/2H	MUREAV 578,225,2005
mutation in microorganisms	/Saccharomyes cerevisiae	68.5 mg/L/16H	MUTAEX 20,105,2004
mutation in microorganisms	/Salmonella typhimurium	3 mg/L/2H (-enzymatic activation step)	MUREAV 578,210,2005
mutation in microorganisms	/Escherichia coli	1 µg/L/2H (-enzymatic activation step)	FCTOD7 48,320,2010
mutation in microorganisms	/Salmonella typhimurium	1.87 mg/plate/48H	MUREAV 535,171,2003
mutation in microorganisms	/Escherichia coli	1.1 mmol/L/2H	MUREAV 535,171,2003
mutation in microorganisms	/Saccharomyes cerevisiae	20 µmol/L/10M	MUREAV 673,53,2009
mutation in microorganisms	/Saccharomyes cerevisiae	316 µmol/L/6H	MUREAV 676,113,2009
mutation in microorganisms	/Saccharomyes cerevisiae	2 µmol/l	MUREAV 547,123,2004
mutation in microorganisms	/Salmonella typhimurium	4 mmol/L	MUTAEX 22,293,2007
mutation in microorganisms	/Saccharomyes cerevisiae	4 mmol/L/1H	EMMUEG 48,728,2007
mutation in microorganisms	/Salmonella typhimurium	0.1 µmol/L/48H	EMMUEG 50,451,2009
mutation in microorganisms	/Escherichia coli	1.2 mmol/L/30M	MUREAV 714,11,2011
mutation in microorganisms	/Salmonella typhimurium	100 µg/plate/48H (-enzymatic activation step)	FCTOD7 50,3360,2012
mutation in microorganisms	/Salmonella typhimurium	1920 mg/L/65H	EMMUEG 57,687,2016
other mutation test systems	other cell types/human	0.5 mmol/L/6H	MUREAV 648,15,2008
other mutation test systems	/Escherichia coli	100 µmol/L	MUREAV 203,81,1988
other mutation test systems	/Salmonella typhimurium	45 mg/L	MUREAV 192,239,1987
other mutation test systems	/Bacillus subtilis	100 µmol/L	MUREAV 4,517,1967
other mutation test systems	other cell types/human	1200 µmol/L	CNREA8 45,2522,1985
phage inhibition capacity	/Escherichia coli	500 ng/well	MUREAV 260,349,1991
sister chromatid exchange	lung/hamster	40 µmol/L	MUREAV 174,21,1986
sister chromatid exchange	ovary/hamster	80 µmol/L	MUREAV 224,269,1989
sister chromatid exchange	/Saccharomyes cerevisiae	0.04 pph	MUREAV 547,123,2004
sister chromatid exchange	ovary/hamster	0.075 mmol/L/1H	MUREAV 649,114,2008
specific locus test	Ascites tumor/mouse	5 mg/L/4H	EMMUEG 42,19,2003
specific locus test	other cell types/mouse	28 µmol/L/4H	MUREAV 678,123,2009
specific locus test	ovary/hamster	400 µmol/L/20M	MUREAV 602,14,2006
specific locus test	/Escherichia coli	50 µmol/L/30M	MUREAV 628,123,2007
specific locus test	/Escherichia coli	1 µmol/L/4H	MUREAV 560,27,2004
specific locus test	kidney/mouse	65 µmol/L	MUREAV 503,69,2002
specific locus test	/Escherichia coli	2.5 mmol/L/10M	MUREAV 508,107,2002
specific locus test	embryo/Drosophila melanogaster	0.12 mole/L/10D	MUREAV 772,25,2014
specific locus test	other cell types/human	144000000 units/L	MUREAV 726,151,2011
specific locus test	oral/Drosophila melanogaster	0.18 mole/L/4D-continuous	MUREAV 703,137,2010
Unscheduled DNA Synthesis	fibroblast/human	1 mmol/L	CALEDQ 5,199,1978
Unscheduled DNA Synthesis	lung/human	600 µg/L	ENMUDM 5,177,1983

Tumorigenic Data and References

Route/Organism	Dose	Effect	Reference
oral/mouse	lowest published toxic dose: 144 gm/kg/26W- continuous	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Gastrointestinal: Tumors	GANNA2 75,17,1984
oral/mouse	toxic dose: 168 gm/kg/30W- continuous	Tumorigenic: Equivocal tumorigenic agent by RTECS criteria Gastrointestinal: Tumors	GANNA2 75,17,1984
skin/mouse	lowest published toxic dose: 4032 mg/kg/18W- intermittent	Tumorigenic: Carcinogenic by RTECS criteria Skin and Appendages: Tumors Tumorigenic: Facilitates action of known carcinogens	ARTODN 78,139,2004

Acute Toxicity Data and References

Route/Organism	Dose	Effect	Reference
In Vitro/Hamster, lung fibroblast	Inhibitor Concentration Low: 100 µmol/L/10M	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,864,2013
In Vitro/Hamster, lung fibroblast	Inhibitor Concentration Low: 50 µmol/L/18H	In Vitro Toxicity Studies: Cell viability (lysosomal damage): neutral red assay etc.	FCTOD7 113,90,2018
In Vitro/Hamster, lung fibroblast	Inhibitor Concentration Low: 100 µmol/L/2H	In Vitro Toxicity Studies: Other assays	FCTOD7 113,90,2018
In Vitro/Hamster, ovary	Inhibitor Concentration Low: 250 µmol/L	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 50,2729,2012
In Vitro/Hamster, ovary	Inhibitor Concentration Low: 250 µmol/L	In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function	FCTOD7 50,2729,2012
In Vitro/Human, blood (whole or unspecified cells)	Inhibitor Concentration Low: 400 µmol/L	In Vitro Toxicity Studies: Cell membrane integrity (prelabeled cells): release of radioactive isotopes ([51Cr], [3H]-thymidine, [3H]-proline, [35S]- or [75Se]-methionine, 5-[125I]-2-deoxy-uridine) or fluorescent dyes (bis-carboxyethyl-carboxyfluorescein (BCECF) or calcein-AM)	TXCYAC 278,242,2010
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 6 µmol/L/24H	In Vitro Toxicity Studies: Apoptosis in vitro	TXAPA9 246,116,2010
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 1 mmol/L/24H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. In Vitro Toxicity Studies: Other assays	TXCYAC 290,230,2011
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 300 µmol/L/1H	In Vitro Toxicity Studies: Other assays	PYTOEY 27,8,2017
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 500 µmol/L/24H	In Vitro Toxicity Studies: Other assays	FTRPAE 109,230,2016
In Vitro/Human, colon tumor	Inhibitor Concentration (50 percent kill): 122 µmol/L/3H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.	TIVIEQ 26,603,2012
In Vitro/Human, colon tumor	Inhibitor Concentration (50 percent kill): 120 µmol/L/3H	In Vitro Toxicity Studies: Cell counting	TIVIEQ 26,603,2012
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 100 µmol/L/2H	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,647,2015
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 10 µmol/L/72H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 29,1156,2015
In Vitro/Human, colon tumor	Inhibitor Concentration Low: 40 mmol/L/3H	Biochemical: Metabolism (intermediary): Effect on mitochondrial function In Vitro Toxicity Studies: Other assays	TOLED5 237,79,2015
In Vitro/Human, embryonic cells	Inhibitor Concentration Low: 100 µmol/L	In Vitro Toxicity Studies: Other assays	TIVIEQ 26,351,2012
In Vitro/Human, endothelium	Inhibitor Concentration Low: 200 µmol/L	In Vitro Toxicity Studies: Other assays	TIVIEQ 28,538,2014
In Vitro/Human, endothelium	Inhibitor Concentration Low: 0.4 mmol/L/1H	In Vitro Toxicity Studies: Other assays	TXCYAC 305,10,2013
In Vitro/Human, endothelium	Inhibitor Concentration Low: 500 µmol/L/4H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	TOLED5 232,149,2015
In Vitro/Human, endothelium	Inhibitor Concentration Low: 300 µmol/L/4H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	JOETD7 143,100,2012
In Vitro/Human, endothelium	Inhibitor Concentration Low: 100 µmol/L/30M	In Vitro Toxicity Studies: Other assays	JOETD7 143,664,2012
In Vitro/Human, endothelium	Inhibitor Concentration Low: 400 µmol/L/4H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 154,428,2014
In Vitro/Human, endothelium	Inhibitor Concentration Low: 200 µmol/L/4H	In Vitro Toxicity Studies: Cell proliferation: DNA incorporation, mitotic index etc.	JOETD7 154,428,2014
In Vitro/Human, endothelium	Inhibitor Concentration Low: 100 µmol/L	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 50,3133,2012
In Vitro/Human, endothelium	Inhibitor Concentration Low: 100 µmol/L	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro Biochemical: Metabolism (intermediary): Effect on mitochondrial function	FCTOD7 50,3133,2012
In Vitro/Human, endothelium	Inhibitor Concentration Low: 200 µmol/L	In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	FCTOD7 50,3133,2012
In Vitro/Human, endothelium	Inhibitor Concentration Low: 200 µmol/L	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 192,423,2016
In Vitro/Human, endothelium	Inhibitor Concentration Low: 0.3 mmol/L/24H	In Vitro Toxicity Studies: Apoptosis in vitro	TIVIEQ 29,638,2015
In Vitro/Human, erythrocytes	Inhibitor Concentration Low: 100 µmol/L/4H	In Vitro Toxicity Studies: Hemolysis in vitro In Vitro Toxicity Studies: Other assays	FCTOD7 49,2292,2011
In Vitro/Human, erythrocytes	Inhibitor Concentration Low: 3.3 mmol/L/2.5H	In Vitro Toxicity Studies: Hemolysis in vitro	FCTOD7 50,141,2012
In Vitro/Human, kidney	Inhibitor Concentration Low: 3 pph	In Vitro Toxicity Studies: Other assays	TIVIEQ 26,206,2012
In Vitro/Human, kidney	Inhibitor Concentration Low: 50 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TXCYAC 290,271,2011
In Vitro/Human, kidney	Inhibitor Concentration Low: 100 µmol/L/10M	In Vitro Toxicity Studies: Other assays	TXCYAC 290,271,2011
In Vitro/Human, leukemia cells	Inhibitor Concentration (50 percent kill): 0.55 mmol/L/72H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TXAPA9 258,351,2012
In Vitro/Human, leukemia cells	Inhibitor Concentration Low: 80 µmol/L/72H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TXAPA9 258,351,2012
In Vitro/Human, leukemia cells	Inhibitor Concentration Low: 80 µmol/L/6H	In Vitro Toxicity Studies: Other assays	TXAPA9 258,351,2012
In Vitro/Human, leukemia cells	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Other assays	JOETD7 153,207,2014
In Vitro/Human, leukemia cells	Inhibitor Concentration Low: 50 µmol/L/15M	In Vitro Toxicity Studies: Other assays	TIVIEQ 26,1161,2012
In Vitro/Human, liver	Inhibitor Concentration Low: 3 mmol/L/4H	In Vitro Toxicity Studies: Other assays	TOLED5 272,60,2017
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 30 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,1,2015
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 200 µmol/L/2H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 108,148,2017
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 400 µmol/L/2H	In Vitro Toxicity Studies: Apoptosis in vitro	FCTOD7 108,148,2017
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 400 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 102,129,2017
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 400 µmol/L/24H	In Vitro Toxicity Studies: Apoptosis in vitro	FCTOD7 102,129,2017
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 100 µmol/L/2H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 149,737,2013
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 0.3 pph/30M	In Vitro Toxicity Studies: Other assays	TIVIEQ 25,1343,2011
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 40 µmol/L/24H	In Vitro Toxicity Studies: Other assays	TOLED5 203,219,2011
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 0.9 mmol/L/24H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	TXAPA9 250,130,2011
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 0.9 mmol/L/30M	In Vitro Toxicity Studies: Other assays	TXAPA9 250,130,2011
In Vitro/Human, liver tumor	Inhibitor Concentration Low: 2 mmol/L/24H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)	TXCYAC 272,32,2010
In Vitro/Human, lung	Inhibitor Concentration Low: 100 µmol/L/2H	In Vitro Toxicity Studies: Other assays	TXAPA9 258,166,2012
In Vitro/Human, lung	Inhibitor Concentration Low: 200 µmol/L/12H	Biochemical: Metabolism (intermediary): Effect on mitochondrial function	FCTOD7 50,2417,2012
In Vitro/Human, lung	Inhibitor Concentration Low: 100 µmol/L	In Vitro Toxicity Studies: Other assays	TIVIEQ 25,1353,2011
In Vitro/Human, lung	Inhibitor Concentration Low: 50 µmol/L/6H	In Vitro Toxicity Studies: Other assays	TXCYAC 287,105,2011
In Vitro/Human, lung tumor	Inhibitor Concentration Low: 100 µmol/L/48H	In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay	TIVIEQ 27,1762,2013
In Vitro/Human, lung tumor	Inhibitor Concentration Low: 100 µmol/L/15M	In Vitro Toxicity Studies: Other assays	TXCYAC 305,109,2013
In Vitro/Human, lung tumor	Inhibitor Concentration Low: 200 µmol/L/2H	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,85,2015
In Vitro/Human, lymphocyte	Inhibitor Concentration Low: 100 µmol/L/15M	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,27,2015
In Vitro/Human, lymphocyte	Inhibitor Concentration Low: 100 µmol/L/10M	In Vitro Toxicity Studies: Other assays	FCTOD7 49,2292,2011
In Vitro/Human, lymphocyte	Inhibitor Concentration Low: 10 µmol/L/10M	In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay In Vitro Toxicity Studies: Apoptosis in vitro	FCTOD7 49,2947,2011
In Vitro/Human, melanoma	Inhibitor Concentration Low: 500 µmol/L/120M	In Vitro Toxicity Studies: Other assays	FCTOD7 50,823,2012
In Vitro/Human, melanoma	Inhibitor Concentration Low: 30 pph/48H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 50,1001,2012
In Vitro/Human, melanoma	Inhibitor Concentration Low: 100 µmol/L/4H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc. In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	NETOX* 32,518,2011
In Vitro/Human, melanoma	Inhibitor Concentration Low: 1 mmol/L/3H	In Vitro Toxicity Studies: Other assays	FCTOD7 50,1454,2012
In Vitro/Human, melanoma	Inhibitor Concentration Low: 100 µmol/L	In Vitro Toxicity Studies: Other assays	FCTOD7 50,1589,2012
In Vitro/Human, melanoma	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	FCTOD7 50,1841,2012
In Vitro/Human, melanoma	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TOLED5 234,151,2015
In Vitro/Human, monocyte	Inhibitor Concentration Low: 0.5 mmol/L/15M	In Vitro Toxicity Studies: Other assays	TXAPA9 246,66,2010
In Vitro/Human, monocyte	Inhibitor Concentration Low: 0.5 mmol/L/30M	Biochemical: Metabolism (intermediary): Effect on mitochondrial function	TXAPA9 246,66,2010
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 1 mmol/L/16H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	FCTOD7 50,492,2012
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 100 µmol/L	In Vitro Toxicity Studies: Other assays	FCTOD7 49,2780,2011
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 500 µmol/L/24H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 136,297,2011
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 400 µmol/L/24H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	JOETD7 142,337,2012
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 400 µmol/L/1H	In Vitro Toxicity Studies: Other assays	JOETD7 142,337,2012
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	TOLED5 228,179,2014
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Apoptosis in vitro	FCTOD7 80,41,2015
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 400 µmol/L/24H	In Vitro Toxicity Studies: Apoptosis in vitro	FCTOD7 80,41,2015
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 25 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 80,41,2015
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 300 µmol/L/2H	In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	TIVIEQ 27,1780,2013
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 300 µmol/L/30M	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1780,2013
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	NRTXDN 33,1086,2012
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 1 mmol/L/1H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	TIVIEQ 26,304,2012
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 50 µmol/L/12H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 110,189,2017
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 100 µmol/L/12H	In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays Biochemical: Metabolism (intermediary): Effect on mitochondrial function	FCTOD7 110,189,2017
In Vitro/Human, neuroblastoma	Inhibitor Concentration Low: 200 µmol/L/12H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. Nutritional and Gross Metabolic: Changes in: Ca	FCTOD7 110,189,2017
In Vitro/Human, skin	Inhibitor Concentration Low: 10.5 mg/L/1H	In Vitro Toxicity Studies: Other assays	TOLED5 239,194,2015
In Vitro/Human, skin	Inhibitor Concentration Low: 200 µmol/L/6H	In Vitro Toxicity Studies: Other assays	TOLED5 233,258,2015
In Vitro/Human, skin	Inhibitor Concentration (20 percent kill): 34.0 mg/L/21H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 27,314,2013
In Vitro/Human, skin	Inhibitor Concentration Low: 100 µmol/L/20M	In Vitro Toxicity Studies: Other assays	JOETD7 148,537,2013
In Vitro/Human, skin	Inhibitor Concentration (75 percent kill): 3.85 mmol/L/3H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 28,120,2014
In Vitro/Human, skin	Inhibitor Concentration Low: 10 mmol/L/18H	In Vitro Toxicity Studies: Other assays	TXCYAC 271,83,2010
In Vitro/Human, skin	Inhibitor Concentration Low: 5 mmol/L/24H	In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	TXAPA9 255,242,2011
In Vitro/Human, skin	Inhibitor Concentration Low: 5 mmol/L/24H	In Vitro Toxicity Studies: Apoptosis in vitro	TXAPA9 255,242,2011
In Vitro/Human, tooth	Inhibitor Concentration Low: 1 mmol/L/12H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	TIVIEQ 27,874,2013
In Vitro/iag	Inhibitor Concentration Low: 50 µmol/L	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,1628,2015
In Vitro/iag	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	NRTXDN 54,161,2016
In Vitro/iag	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Other assays	NRTXDN 54,161,2016
In Vitro/jah	Inhibitor Concentration Low: 40 µmol/L/24H	In Vitro Toxicity Studies: Other assays	TOLED5 203,219,2011
In Vitro/jah	Inhibitor Concentration Low: 1 mmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	NRTXDN 33,1368,2012
In Vitro/jah	Inhibitor Concentration Low: 1 mmol/L/30M	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc.	PYTOEY 22,847,215
In Vitro/jah	Inhibitor Concentration Low: 1 mmol/L/150M	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.)	PYTOEY 22,847,215
In Vitro/jda	Inhibitor Concentration Low: 250 µmol/L/12H	In Vitro Toxicity Studies: Other assays	TIVIEQ 29,1358,2015
In Vitro/jda	Inhibitor Concentration Low: 500 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 29,1358,2015
In Vitro/jda	Inhibitor Concentration Low: 750 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	FCTOD7 112,76,2018
In Vitro/jma	Inhibitor Concentration Low: 100 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TXAPA9 257,1,2011
In Vitro/jrd	Inhibitor Concentration Low: 0.4 mmol/L/1H	In Vitro Toxicity Studies: Other assays	TXCYAC 305,10,2013
In Vitro/jtg	Inhibitor Concentration Low: 6 pph	In Vitro Toxicity Studies: Other assays Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	JOETD7 153,119,2014
In Vitro/jti	Inhibitor Concentration Low: 50 µmol/L/12H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 26,429,2012
In Vitro/jti	Inhibitor Concentration Low: 100 µmol/L/12H	In Vitro Toxicity Studies: Apoptosis in vitro	TIVIEQ 26,429,2012
In Vitro/jti	Inhibitor Concentration Low: 1 mmol/L/30M	Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Peptidases	TXAPA9 244,315,2010
In Vitro/jvx	Inhibitor Concentration Low: 300 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1877,2013
In Vitro/max	Inhibitor Concentration Low: 1 mmol/L	In Vitro Toxicity Studies: Other assays	TXCYAC 290,342,2011
In Vitro/mga	Inhibitor Concentration Low: 0.68 mg/L/5D	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1503,2013
In Vitro/mlb	Inhibitor Concentration Low: 1 mmol/L/24H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.	JOETD7 193,657,2016
In Vitro/Mouse, embryo	Inhibitor Concentration Low: 5 µmol/L/1H	Reproductive: Other effects to embryo or fetus	JOETD7 154,600,2014
In Vitro/Mouse, fibroblast	Inhibitor Concentration Low: 0.25 mmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 150,223,2013
In Vitro/Mouse, fibroblast	Inhibitor Concentration (50 percent kill): 0.26 mmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	PYTOEY 19,1178,2012
In Vitro/Mouse, fibroblast	Inhibitor Concentration (75 percent kill): 2.2 mmol/L/3H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TIVIEQ 28,120,2014
In Vitro/Mouse, fibroblast	Inhibitor Concentration Low: 0.6 mmol/L/12H	In Vitro Toxicity Studies: Other assays	PYTOEY 34,76,2017
In Vitro/Mouse, fibroblast	Inhibitor Concentration Low: 0.5 mmol/L/1H	In Vitro Toxicity Studies: Other assays	TOLED5 276,129,2017
In Vitro/Mouse, fibroblast	Inhibitor Concentration Low: 5 mmol/L/3H	In Vitro Toxicity Studies: Apoptosis in vitro	TIVIEQ 29,638,2015
In Vitro/Mouse, liver	Inhibitor Concentration Low: 1 mmol/L/6H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	JOETD7 155,132,2014
In Vitro/Mouse, macrophage	Inhibitor Concentration Low: 100 µmol/L/3H	In Vitro Toxicity Studies: Other assays	JOETD7 156,61,2014
In Vitro/Mouse, macrophage	Inhibitor Concentration Low: 400 µmol/L/2H	In Vitro Toxicity Studies: Other assays	TXAPA9 246,91,2010
In Vitro/Mouse, macrophage	Inhibitor Concentration Low: 500 µmol/L/10M	In Vitro Toxicity Studies: Other assays	TXAPA9 255,32,2011
In Vitro/Mouse, macrophage	Inhibitor Concentration Low: 0.5 mmol/L/6H	In Vitro Toxicity Studies: Apoptosis in vitro	TIVIEQ 29,638,2015
In Vitro/Mouse, macrophage	Inhibitor Concentration Low: 300 µmol/L/30M	In Vitro Toxicity Studies: Other assays	TOLED5 239,205,2015
In Vitro/Mouse, neuroblastom	Inhibitor Concentration (50 percent kill): 10 µmol/L/24H	In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay	TXAPA9 258,208,2012
In Vitro/Mouse, neuroblastom	Inhibitor Concentration Low: 2 mmol/L/10H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FTRPAE 83,223,2012
In Vitro/Mouse, neuroblastom	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 148,980,2013
In Vitro/Mouse, neurons	Inhibitor Concentration (50 percent kill): 1.2 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TXAPA9 256,369,2011
In Vitro/mqa	Inhibitor Concentration Low: 1 µmol/L	In Vitro Toxicity Studies: Other assays	TOLED5 234,13,2015
In Vitro/mtg	Inhibitor Concentration Low: 1 µmol/L/2H	In Vitro Toxicity Studies: Apoptosis in vitro	TOLED5 225,86,2014
In Vitro/mvb	Inhibitor Concentration Low: 1 mmol/L/3H	In Vitro Toxicity Studies: Other assays Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Catalases	TIVIEQ 25,2025,2011
In Vitro/mzx	Inhibitor Concentration (50 percent kill): 3.7 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TXAPA9 256,369,2011
In Vitro/mzx	Inhibitor Concentration Low: 5 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TXAPA9 256,369,2011
In Vitro/paa	Inhibitor Concentration Low: 20 µmol/L/10M	Brain and Coverings: Recordings from specific areas of CNS In Vitro Toxicity Studies: Other assays	JOETD7 134,147,2011
In Vitro/paa	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Other assays	TXCYAC 305,71,2013
In Vitro/paa	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	NRTXDN 55,131,2016
In Vitro/paa	Inhibitor Concentration Low: 200 µmol/L/24H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell proliferation: DNA incorporation, mitotic index etc. In Vitro Toxicity Studies: Apoptosis in vitro	NRTXDN 55,131,2016
In Vitro/paa	Inhibitor Concentration Low: 1 mmol/L/1H	In Vitro Toxicity Studies: Apoptosis in vitro	NRTXDN 52,210,2016
In Vitro/pah	Inhibitor Concentration Low: 20 µmol/L/72H	In Vitro Toxicity Studies: Cell protein synthesis	FCTOD7 67,212,2014
In Vitro/pax	Inhibitor Concentration Low: 25 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 80,41,2015
In Vitro/pda	Inhibitor Concentration Low: 300 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	FCTOD7 49,2131,2011
In Vitro/pda	Inhibitor Concentration Low: 1 mmol/L	In Vitro Toxicity Studies: Other assays	FCTOD7 49,2131,2011
In Vitro/pkf	Inhibitor Concentration Low: 40 µmol/L	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	JOETD7 188,159,2016
In Vitro/pra	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TOLED5 205,173,2011
In Vitro/pzx	Inhibitor Concentration Low: 10 mmol/L/2H	Nutritional and Gross Metabolic: Changes in: Other metals	TXCYAC 276,27,2010
In Vitro/pzx	Inhibitor Concentration Low: 10 µmol/L/2H	In Vitro Toxicity Studies: Other assays	TXCYAC 276,27,2010
In Vitro/Rat, cerebellum	Inhibitor Concentration Low: 100 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TIVIEQ 28,1206,2014
In Vitro/Rat, endocrine cell (tissues)	Inhibitor Concentration Low: 200 µmol/L/4H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Other assays	JOETD7 193,408,2016
In Vitro/Rat, endocrine tumor	Inhibitor Concentration Low: 150 µmol/L/24H	In Vitro Toxicity Studies: Cell morphology: overgrowth of cell appendixes etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	TIVIEQ 26,907,2012
In Vitro/Rat, endocrine tumor	Inhibitor Concentration Low: 200 µmol/L/4H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	JOETD7 134,275,2011
In Vitro/Rat, endocrine tumor	Inhibitor Concentration Low: 2 µmol/L/1H	Endocrine: Other changes	TXAPA9 258,216,2012
In Vitro/Rat, endocrine tumor	Inhibitor Concentration Low: 50 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	NRTXDN 33,138,2012
In Vitro/Rat, endocrine tumor	Inhibitor Concentration Low: 150 µmol/L/24H	In Vitro Toxicity Studies: Other assays	PYTOEY 20,939,2013
In Vitro/Rat, endocrine tumor	Inhibitor Concentration Low: 0.1 mmol/L/30M	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	JOETD7 147,645,2013
In Vitro/Rat, fibroblast	Inhibitor Concentration Low: 1 µmol/L/24H	Biochemical: Metabolism (intermediary): Other proteins	JOETD7 145,152,2013
In Vitro/Rat, fibroblast	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell proliferation: DNA incorporation, mitotic index etc. Biochemical: Metabolism (intermediary): Other proteins	JOETD7 145,152,2013
In Vitro/Rat, fibroblast	Inhibitor Concentration Low: 10 µmol/L/30M	In Vitro Toxicity Studies: Other assays	JOETD7 145,152,2013
In Vitro/Rat, fibroblast	Inhibitor Concentration Low: 100 µmol/L/30M	In Vitro Toxicity Studies: Other assays Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	JOETD7 145,152,2013
In Vitro/Rat, glioma	Inhibitor Concentration (50 percent kill): 143 µmol/L/24H	In Vitro Toxicity Studies: Cell protein synthesis	FCTOD7 49,2398,2011
In Vitro/Rat, glioma	Inhibitor Concentration (50 percent kill): 686 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	FCTOD7 49,2398,2011
In Vitro/Rat, glioma	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell protein synthesis	FCTOD7 49,2398,2011
In Vitro/Rat, liver	Inhibitor Concentration Low: 0.01 mmol/L	In Vitro Toxicity Studies: Other assays	TXCYAC 278,356,2010
In Vitro/Rat, lung	Inhibitor Concentration (50 percent kill): 0.214 mmol/L/24H	In Vitro Toxicity Studies: Cell counting	TIVIEQ 18,79,2004
In Vitro/Rat, myocard	Inhibitor Concentration Low: 400 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	JOETD7 149,720,2013
In Vitro/Rat, myocard	Inhibitor Concentration Low: 150 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TOLED5 215,219,2012
In Vitro/Rat, myocard	Inhibitor Concentration Low: 600 µmol/L/6H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	JOETD7 153,552,2014
In Vitro/Rat, myocard	Inhibitor Concentration Low: 600 µmol/L/30M	In Vitro Toxicity Studies: Other assays	JOETD7 153,552,2014
In Vitro/Rat, myocard	Inhibitor Concentration Low: 0.1 mmol/L/3H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	FTRPAE 88,44,2013
In Vitro/Rat, myocard	Inhibitor Concentration Low: 100 µmol/L/4H	In Vitro Toxicity Studies: Cell Viability (cell death), unspecified assay	FTRPAE 90,185,2013
In Vitro/Rat, myocard	Inhibitor Concentration Low: 200 µmol/L/4H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Peptidases	TIVIEQ 27,1686,2013
In Vitro/Rat, myocard	Inhibitor Concentration Low: 200 µmol/L/1H	In Vitro Toxicity Studies: Other assays	TIVIEQ 27,1686,2013
In Vitro/Rat, myocard	Inhibitor Concentration (50 percent kill): 400 µmol/L/24H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc.	TXCYAC 303,54,2013
In Vitro/Rat, myocard	Inhibitor Concentration Low: 400 µmol/L/24H	In Vitro Toxicity Studies: Other assays	TXCYAC 303,54,2013
In Vitro/Rat, neurons	Inhibitor Concentration Low: 50 µmol/L/4H	In Vitro Toxicity Studies: Cell membrane integrity: Cytoplasmic enzymes leakage (lactate dehydrogenase, ATP enzymes etc.) In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	NRTXDN 36,24,2013
In Vitro/Rat, neurons	Inhibitor Concentration Low: 120 µmol/L/10H	In Vitro Toxicity Studies: Cell viability (mitochondrial reductase assays): MTT, XTT, MTS, WSTs assays etc. In Vitro Toxicity Studies: Apoptosis in vitro	JOETD7 134,147,2011
In Vitro/Rat, neurons	Inhibitor Concentration Low: 10 mmol/L/0.5M	Nutritional and Gross Metabolic: Changes in: Ca In Vitro Toxicity Studies: Other assays	JOETD7 134,147,2011
In Vitro/Rat, neurons	Inhibitor Concentration Low: 25 µmol/L/24H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc.	FCTOD7 49,2862,2011
In Vitro/Rat, neurons	Inhibitor Concentration Low: 100 µmol/L/24H	In Vitro Toxicity Studies: Cell metabolic activity: Alamar Blue assay etc. In Vitro Toxicity Studies: Apoptosis in vitro In Vitro Toxicity Studies: Other assays	FCTOD7 49,2862,2011
In Vitro/Rat, neurons	Inhibitor Concentration Low: 100 µmol/L/3H	In Vitro Toxicity Studies: Cell viability (dye exclusion): trypan blue assay etc.	TXAPA9 254,65,2011
In Vitro/Rat, neurons	Inhibitor Concentration Low: 100 µmol/L/45M	In Vitro Toxicity Studies: Other assays	NRTXDN 53,302,2016
In Vitro/Rat, testis	Inhibitor Concentration Low: 10 µmol/L/3H	In Vitro Toxicity Studies: Other assays	TIVIEQ 26,950,2012
In Vitro/Rat, testis	Inhibitor Concentration Low: 1 µmol/L/24H	In Vitro Toxicity Studies: Other assays	TIVIEQ 26,950,2012
inhalation/human	lowest published toxic concentration: 10 mg/m³	Skin: After topical application: Primary irritation	VCVN1* -,18,1998
inhalation/human	lowest published toxic concentration: 20 mg/m³	Peripheral Nerve and Sensation: Flaccid paralysis with appropriate anesthesia Behavioral: Tetany Cardiac: Arrythmias (indlucing changes in conduction)	VCVN1* -,18,1998
inhalation/human	lowest published toxic concentration: 2.2 ppm/2H	Olfaction: Other olfaction effects Lung, Thorax, or Respiration: Other changes	TOLED5 212,222,2012
inhalation/mammal (species unspecified)	lowest published toxic concentration: 60 mg/m³/4H	Skin: After topical application: Primary irritation	VCVN1* -,17,1998
inhalation/mouse	Lowest published lethal concentration: 227 ppm		AEHLAU 4,327,1962
inhalation/rat	lethal concentration (50 percent kill): 2 gm/m³/4H	Lung, Thorax, or Respiration: Pulmonary emboli	GTPZAB 21(10),22,1977
inhalation/rat	lethal concentration (50 percent kill): 2000 mg/m³		VCVN1* -,17,1998
intraperitoneal/mouse	lethal dose (50 percent kill): 880 mg/kg		VCVN1* -,17,1998
intravenous/Dog	lowest published toxic dose: 0.003 mg/kg	Behavioral: Excitement Behavioral: Tetany Lung, Thorax, or Respiration: Dyspnea	VCVN1* -,17,1998
intravenous/horse, donkey	lowest published toxic dose: 40 µg/kg	Cardiac: Pulse rate increased without fall in BP Lung, Thorax, or Respiration: Dyspnea Gastrointestinal: Hypermotility, diarrhea	VCVN1* -,17,1998
intravenous/rabbit	lowest published lethal dose: 0.004 mg/kg	Behavioral: Tremor Behavioral: Ataxia Lung, Thorax, or Respiration: Dyspnea	VCVN1* -,17,1998
intravenous/rabbit	lethal dose (50 percent kill): 15 gm/kg	Behavioral: Convulsions or effect on seizure threshold	MRLR** #75,1951
oral/mouse	lethal dose (50 percent kill): 2000 mg/kg		VCVN1* -,17,1998
oral/rat	lethal dose (50 percent kill): 4050 mg/kg		VCVN1* -,17,1998
oral/rat	lethal dose (50 percent kill): 376 mg/kg	Gastrointestinal: Peritonitis Blood: Pigmented or nucleated red blood cells Blood: Changes in leukocyte (WBC) count	STGNBT -,39,1999
skin/mouse	lethal dose (50 percent kill): 1072 mg/kg		VCVN1* -,17,1998
skin/pig	lowest published lethal dose: 2 gm/kg	Behavioral: Convulsions or effect on seizure threshold	MRLR** #75,1951
skin/rabbit	lowest published lethal dose: 500 mg/kg	Behavioral: Convulsions or effect on seizure threshold	MRLR** #75,1951
skin/rat	lethal dose (50 percent kill): 4060 mg/kg	Lung, Thorax, or Respiration: Pulmonary emboli	GTPZAB 21(10),22,1977
subcutaneous/mouse	lethal dose (50 percent kill): 1072 mg/kg		GISAAA 48(6),28,1983
subcutaneous/rat	lethal dose (50 percent kill): 620 mg/kg		VCVN1* -,17,1998
Tank with water/other fish	lowest published toxic concentration: 200 µmol/L/2H	Musculoskeletal: Other changes Biochemical: Metabolism (intermediary): Lipids including transport Biochemical: Metabolism (intermediary): Other	FCTOD7 53,205,2013

Other Multiple Dose Data and References

Route/Organism	Dose	Effect	Reference
inhalation/Dog	lowest published toxic concentration: 7 ppm/6H/26W- intermittent	Skin: After systemic exposure: Dermatitis, other Skin and Appendages: Other: Hair	AMIHBC 10,319,1954
inhalation/mouse	lowest published toxic concentration: 57 ppm/6H/6W- intermittent	Skin: After systemic exposure: Dermatitis, irritative Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	AMIHBC 10,319,1954
inhalation/rat	lowest published toxic concentration: 67 ppm/6H/6W- intermittent	Skin: After systemic exposure: Dermatitis, irritative Related to Chronic Data: Death in the "MULTIPLE DOSE" data type field	AMIHBC 10,319,1954
inhalation/rat	lowest published toxic concentration: 10 mg/m³/5H/17W- intermittent	Lung, Thorax, or Respiration: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Monoamine oxidase Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Dehydrogenases	GTPZAB 21(10),22,1977
inhalation/rat	lowest published toxic concentration: 10 mg/m³/5H/8W- intermittent	Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	VCVN1* -,18,1998
inhalation/rat	lowest published toxic concentration: 10 mg/m³/5H/17W- intermittent	Blood: Changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Multiple enzyme effects	VCVN1* -,18,1998
intraperitoneal/non-mammalian species	lowest published toxic dose: 12 mg/kg/6D- intermittent	Liver: Other changes	TOXID9 66,67,2002
intraperitoneal/rat	lowest published toxic dose: 1190.7 mg/kg/10W- intermittent	Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Catalases Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	FCTOD7 50,1860,2012
oral/rabbit	lowest published toxic dose: 8.75 mg/kg/25W- continuous	Endocrine: Effect on menstrual cycle Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Nutritional and Gross Metabolic: Weight loss or decreased weight gain	VCVN1* -,19,1988
oral/rat	lowest published toxic dose: 8.75 mg/kg/25W- continuous	Endocrine: Effect on menstrual cycle Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) Nutritional and Gross Metabolic: Weight loss or decreased weight gain	VCVN1* -,19,1988
oral/rat	lowest published toxic dose: 1400 mg/kg/14D- intermittent	Cardiac: Other changes Liver: Other changes Biochemical: Enzyme inhibition, induction, or change in blood or tissue levels: Other oxidoreductases	FCTOD7 49,898,2011

Reviews

Organization	Standard	Reference
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-time-weighted average 1 ppm	DTLVS* TLV/BEI,2013
American Conference of Governmental Industrial Hygienists (ACGIH)	Threshold Limit Value-Confirmed animal carcinogen	DTLVS* TLV/BEI,2013
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Limited Evidence	IMEMDT 36,285,1985
International Agency for Research on Cancer (IARC)	Cancer Review:Animal Limited Evidence	IMEMDT 71,671,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Human No Adequate Data	IMEMDT 36,285,1985
International Agency for Research on Cancer (IARC)	Cancer Review:Human Inadequate Evidence	IMEMDT 71,671,1999
International Agency for Research on Cancer (IARC)	Cancer Review:Group 3	IMEMDT 71,671,1999
TOXICOLOGY REVIEW		32RWA4 1,239,1976
TOXICOLOGY REVIEW		MUREAV 566,99,2004
TOXICOLOGY REVIEW		MUREAV 544,179,2003
TOXICOLOGY REVIEW		TXAPA9 197,144,2004
TOXICOLOGY REVIEW		FCTOD7 44,301,2006
TOXICOLOGY REVIEW		MUTAEX 19,251,2004
TOXICOLOGY REVIEW		MUREAV 616,11,2007
TOXICOLOGY REVIEW		ENTOX* -,543,2005
TOXICOLOGY REVIEW		MUREAV 635,90,2007
TOXICOLOGY REVIEW		MUTAEX 19,3,2004
TOXICOLOGY REVIEW		MUREAV 584,1,2005
TOXICOLOGY REVIEW		MUREAV 533,65,2003
TOXICOLOGY REVIEW		MUREAV 533,133,2003
TOXICOLOGY REVIEW		MUREAV 533,183,2003
TOXICOLOGY REVIEW		MUTAEX 19,169,2004
TOXICOLOGY REVIEW		MUREAV 658,154,2008
TOXICOLOGY REVIEW		MUREAV 659,15,2008
TOXICOLOGY REVIEW		REPTED 25,291,2007
TOXICOLOGY REVIEW		MUREAV 657,84,2008
TOXICOLOGY REVIEW		HUTOX* -,683,1996
TOXICOLOGY REVIEW		MUREAV 672,1,2009
TOXICOLOGY REVIEW		MUREAV 543,191,2003
TOXICOLOGY REVIEW		MUREAV 681,3,2009
TOXICOLOGY REVIEW		BJMRDK 41,545,2008
TOXICOLOGY REVIEW		MUREAV 681,24,2009
TOXICOLOGY REVIEW		MUREAV 674,3,2009
TOXICOLOGY REVIEW		MUREAV 674,36,2009
TOXICOLOGY REVIEW		MUREAV 674,31,2009
TOXICOLOGY REVIEW		MUREAV 681,44,2009
TOXICOLOGY REVIEW		MUREAV 681,51,2009
TOXICOLOGY REVIEW		MUREAV 674,62,2009
TOXICOLOGY REVIEW		MUREAV 674,73,2009
TOXICOLOGY REVIEW		MUREAV 674,137,2009
TOXICOLOGY REVIEW		MUREAV 674,85,2009
TOXICOLOGY REVIEW		MUREAV 681,33,2009
TOXICOLOGY REVIEW		MUREAV 681,68,2009
TOXICOLOGY REVIEW		MUTAEX 17,529,2002
TOXICOLOGY REVIEW		MUTAEX 17,495,2002
TOXICOLOGY REVIEW		FCTOD7 47,1287,2009
TOXICOLOGY REVIEW		MUREAV 667,98,2009
TOXICOLOGY REVIEW		MUREAV 682,39,2009
TOXICOLOGY REVIEW		MUTAEX 22,161,2007
TOXICOLOGY REVIEW		MUTAEX 21,219,2006
TOXICOLOGY REVIEW		MUTAEX 21,225,2006
TOXICOLOGY REVIEW		MUREAV 579,6,2005
TOXICOLOGY REVIEW		MUREAV 669,8,2009
TOXICOLOGY REVIEW		MUREAV 682,94,2009
TOXICOLOGY REVIEW		MUTAEX 23,153,2008
TOXICOLOGY REVIEW		MUREAV 704,152,2010
TOXICOLOGY REVIEW		MUTAEX 23,271,2008
TOXICOLOGY REVIEW		TXAPA9 243,239,2010
TOXICOLOGY REVIEW		MUREAV 690,3,2010
TOXICOLOGY REVIEW		MUREAV 705,107,2010
TOXICOLOGY REVIEW		MUTAEX 24,383,2009
TOXICOLOGY REVIEW		MUTAEX 23,191,2008
TOXICOLOGY REVIEW		MUTAEX 26,101,2011
TOXICOLOGY REVIEW		MUTAEX 26,231,2011
TOXICOLOGY REVIEW		MUTAEX 26,69,2011
TOXICOLOGY REVIEW		MUREAV 685,3,2010
TOXICOLOGY REVIEW		MUREAV 727,1,2011
TOXICOLOGY REVIEW		MUTAEX 26,193,2011
TOXICOLOGY REVIEW		MUTAEX 26,51,2011
TOXICOLOGY REVIEW		MUTAEX 26,199,2011
TOXICOLOGY REVIEW		MUREAV 711,13,2011
TOXICOLOGY REVIEW		MUREAV 711,158,2011
TOXICOLOGY REVIEW		MUREAV 728,47,2011
TOXICOLOGY REVIEW		MUREAV 717,54,2011
TOXICOLOGY REVIEW		MUREAV 750,60,2012
TOXICOLOGY REVIEW		MUREAV 26,253,2011
TOXICOLOGY REVIEW		MUREAV 728,35,2011
TOXICOLOGY REVIEW		MUREAV 728,12,2011
TOXICOLOGY REVIEW		MUREAV 750,107,2012
TOXICOLOGY REVIEW		REPTED 33,188,2012
TOXICOLOGY REVIEW		MUREAV 736,122,2012
TOXICOLOGY REVIEW		MUREAV 751,15,2012
TOXICOLOGY REVIEW		MUREAV 751,77,2012
TOXICOLOGY REVIEW		MUREAV 751,247,2012
TOXICOLOGY REVIEW		MUREAV 751,158,2012
TOXICOLOGY REVIEW		REPTED 35,165,2013
TOXICOLOGY REVIEW		MUREAV 752,25,2013
TOXICOLOGY REVIEW		MUREAV 733,4,2012
TOXICOLOGY REVIEW		MUREAV 752,61,2013
TOXICOLOGY REVIEW		MUTAEX 25,101,2010
TOXICOLOGY REVIEW		MUREAV 733,39,2012
TOXICOLOGY REVIEW		MUREAV 752,99,2013
TOXICOLOGY REVIEW		MUREAV 752,72,2013
TOXICOLOGY REVIEW		NRTXDN 32,563,2011
TOXICOLOGY REVIEW		REPTED 34,298,2012
TOXICOLOGY REVIEW		MUREAV 752,153,2012
TOXICOLOGY REVIEW		MUTAEX 23,143,2008
TOXICOLOGY REVIEW		MUTAEX 23,171,2008
TOXICOLOGY REVIEW		MUREAV 743-744,67,2013
TOXICOLOGY REVIEW		EMMUEG 53,683,2012
TOXICOLOGY REVIEW		MUREAV 753,147,2013
TOXICOLOGY REVIEW		MUREAV 744,8,2012
TOXICOLOGY REVIEW		MUREAV 759,27,2014
TOXICOLOGY REVIEW		MUREAV 759,49,2014
TOXICOLOGY REVIEW		EMMUEG 55,278,2014
TOXICOLOGY REVIEW		TOLED5 199,203,2010
TOXICOLOGY REVIEW		MUREAV 761,1,2014
TOXICOLOGY REVIEW		MUREAV 750,31,2013
TOXICOLOGY REVIEW		MUREAV 762,133,2014
TOXICOLOGY REVIEW		MUTAEX 30,89,2014
TOXICOLOGY REVIEW		MUTAEX 30,1,2015
TOXICOLOGY REVIEW		MUREAV 769,34,2014
TOXICOLOGY REVIEW		MUREAV 763,181,2015
TOXICOLOGY REVIEW		MUREAV 711,193,2011
TOXICOLOGY REVIEW		MUREAV 711,123,2011
TOXICOLOGY REVIEW		MUREAV 733,61,2012
TOXICOLOGY REVIEW		MUREAV 733,100,2012
TOXICOLOGY REVIEW		MUREAV 765,56,2015
TOXICOLOGY REVIEW		MUREAV 776,31,2015
TOXICOLOGY REVIEW		MUREAV 776,84,2015
TOXICOLOGY REVIEW		MUREAV 776,118,2015
TOXICOLOGY REVIEW		MUREAV 733,1,2012
TOXICOLOGY REVIEW		MUTAEX 30,459,2015
TOXICOLOGY REVIEW		MUTAEX 31,17,2016
TOXICOLOGY REVIEW		MUREAV 793,176,2015
TOXICOLOGY REVIEW		MUREAV 766,1,2015
TOXICOLOGY REVIEW		MUREAV 764,16,2015
TOXICOLOGY REVIEW		MUREAV 766,48,2015
TOXICOLOGY REVIEW		MUREAV 767,67,2016
TOXICOLOGY REVIEW		MUREAV 767,59,2016
TOXICOLOGY REVIEW		MUREAV 743-744,160,2013
TOXICOLOGY REVIEW		MUREAV 767,92,2016
TOXICOLOGY REVIEW		MUREAV 767,8,2016
TOXICOLOGY REVIEW		MUREAV 802,1,2016
TOXICOLOGY REVIEW		MUREAV 770,12,2016
TOXICOLOGY REVIEW		MUREAV 770,119,2016
TOXICOLOGY REVIEW		MUREAV 770,170,2016
TOXICOLOGY REVIEW		MUREAV 773,134,2017
TOXICOLOGY REVIEW		MUREAV 771,99,2017
TOXICOLOGY REVIEW		MUREAV 774,12,2017
TOXICOLOGY REVIEW		MUREAV 774,46,2017
TOXICOLOGY REVIEW		MUREAV 774,25,2017
TOXICOLOGY REVIEW		MUREAV 803-805,56,2017
TOXICOLOGY REVIEW		MUREAV 827,1,2018
TOXICOLOGY REVIEW		REPTED 73,105,2017
TOXICOLOGY REVIEW		FCTOD7 108,365,2017
TOXICOLOGY REVIEW		MUREAV 776,1,2018
TOXICOLOGY REVIEW		MUREAV 776,70,2018
TOXICOLOGY REVIEW		MUTAEX 33,9,2018
TOXICOLOGY REVIEW		MUREAV 777,64,2018
TOXICOLOGY REVIEW		EMMUEG 57,350,2016
TOXICOLOGY REVIEW		MUREAV 778,13,2018

Standards and Regulations

Organization	Standard	Reference
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1988 PESTICIDE SUBJECT TO REGISTRATION OR RE-REGISTRATION		FEREAC 54,7740,1989
Environmental Protection Agency (EPA) Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) 1998 STATUS OF PESTICIDES	RED Completed	RBREV* -,330,1998
Mine Safety and Health Administration (MSHA) STANDARD-air	time-weighted average 1 ppm (1.4 mg/m³)	DTLVS* 3,131,1971
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN check ACGIH TLV;
Occupational Exposure Limit IN SINGAPORE, VIETNAM check ACGIH TLV
Occupational Exposure Limit-AUSTRALIA	time-weighted average 1 ppm (1.4 mg/m³), JUL2008
Occupational Exposure Limit-AUSTRIA	MAK-TMW 1 ppm (1.4 mg/m³);KZW 2 ppm (2.8 mg/m³), 2007
Occupational Exposure Limit-BELGIUM	time-weighted average 1 ppm (1.4 mg/m³), MAR2002
Occupational Exposure Limit-DENMARK	time-weighted average 1 ppm (1.4 mg/m³), MAY2011
Occupational Exposure Limit-FINLAND	time-weighted average 1 ppm (1.4 mg/m³), short term exposure limit 3 ppm (4.2 mg/m³), NOV2011
Occupational Exposure Limit-FRANCE	VME 1 ppm (1.5 mg/m³), FEB2006
Occupational Exposure Limit-GERMANY	MAK 0.5 ppm (0.71 mg/m³), 2011
Occupational Exposure Limit-ICELAND	time-weighted average 1 ppm (1.4 mg/m³), NOV2011
Occupational Exposure Limit-KOREA	time-weighted average 1 ppm (1.5 mg/m³), 2006
Occupational Exposure Limit-MEXICO	time-weighted average 1 ppm (1.5 mg/m³);short term exposure limit 2 ppm (3 mg/m³), 2004
Occupational Exposure Limit-NEW ZEALAND	time-weighted average 1 ppm (1.4 mg/m³), JAN2002
Occupational Exposure Limit-NORWAY	time-weighted average 1 ppm (1.4 mg/m³), JAN1999
Occupational Exposure Limit-PERU	time-weighted average 1 ppm (1,4 mg/m³), JUL2005
Occupational Exposure Limit-SWEDEN	time-weighted average 1 ppm (1.4 mg/m³), ceiling concentration 2 ppm (3 mg/m³), JUN2005
Occupational Exposure Limit-SWITZERLAND	ceiling concentration 0.5 ppm (0.71 mg/m³), JAN2011
Occupational Exposure Limit-THE NETHERLANDS	MAC-TGG 1.4 mg/m³, 2003
Occupational Exposure Limit-THE PHILIPPINES	time-weighted average 1 ppm (1.4 mg/m³), JAN1993
Occupational Exposure Limit-TURKEY	time-weighted average 1 ppm (1.4 mg/m³), JAN1993
Occupational Exposure Limit-UNITED KINGDOM	time-weighted average 1 ppm (1.4 mg/m³);short term exposure limit 2 ppm (2.8 mg/m³), OCT2007
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction)	8H time-weighted average 1 ppm (1.4 mg/m³)	CFRGBR 29,1926.55,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Federal Contractors)	8H time-weighted average 1 ppm (1.4 mg/m³)	CFRGBR 41,50-204.50,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry)	8H time-weighted average 1 ppm (1.4 mg/m³)	CFRGBR 29,1910.1000,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards)	8H time-weighted average 1 ppm (1.4 mg/m³)	CFRGBR 29,1915.1000,1993

NIOSH Documentation and Surveillance

Organization	Standard	Reference
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO HYDROGEN PEROXIDE-air	10H time-weighted average 1.0 ppm	NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983	Hazard Code 38605; Number of Industries 171; Total Number of Facilities 22930; Number of Occupations 142; Total Number of Employees Exposed 1006752; Total Number of Female Employees Exposed 727702
National Occupational Hazard Survey 1974	Hazard Code 38605; Number of Industries 168; Total Number of Facilities 19597; Number of Occupations 83; Total Number of Employees Exposed 422227

Status in Federal Agencies

Organization	Reference
EPA TSCA Section 8(b) CHEMICAL INVENTORY
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA Section 8(e) Risk Notification, 8EHQ-0892-8799
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001

Page last reviewed: November 16, 2018

Content source: National Institute for Occupational Safety and Health